ライフサイエンスコーパス: Bruton's tyrosine kinase

1 her revealed that DOK3 was phosphorylated by Bruton's tyrosine kinase.

2 ectors phospholipase C (PLC)gamma2, Akt, and Bruton's tyrosine kinase.

3 on factor and a target of phosphorylation by Bruton's tyrosine kinase.

4 ction of TEC family tyrosine kinases such as Bruton's tyrosine kinase.

5 r II-I), which encodes BAP-135, a target for Bruton's tyrosine kinase.

6 These results are extended into Btk (Bruton's tyrosine kinase), a Tec family kinase linked to

7 mast cell proliferation was not dependent on Bruton's tyrosine kinase, a downstream effector of PI3K,

8 Moreover, we observed that Bruton's tyrosine kinase, a downstream target of MYD88 s

9 Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase, a key enzyme in the signaling

10 pamycin, histone deacetylase, bcl-2, and the Bruton's tyrosine kinase, a pivotal enzyme in the BCR pa

11 88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.

12 aRIIb1 with BCR inhibits PIP3-dependent Btk (Bruton's tyrosine kinase) activation and the Btk-depende

13 19, as demonstrated by reduced activation of Bruton's tyrosine kinase and extracellular signal-regula

14 significant and dose-dependent inhibition of Bruton's tyrosine kinase and indirectly its downstream s

15 rreversible small-molecule inhibitor of both Bruton's tyrosine kinase and interleukin-2 inducible kin

16 right function is dependent upon both active Bruton's tyrosine kinase and its substrate, the transcri

17 CR-mediated DAG production is dependent upon Bruton's tyrosine kinase and phospholipase C-gamma2, enz

18 Consistent with the essential role for Bruton's tyrosine kinase and phospholipase Cgamma2 in me

19 phorylation of SYK and its immediate targets Bruton's tyrosine kinase and phospholipase Cgamma2.

20 In contrast to the highly successful Bruton's tyrosine kinase and PI3K inhibitors that inhibi

21 ant leukaemic cells expressed high levels of Bruton's tyrosine kinase and two ATP synthetases (ATP5A1

22 e proteins identified by MALDI-TOF including Bruton's tyrosine kinase and X-linked inhibitor of apopt

23 In osteoclasts, loss of CypA activates BtK (Bruton's tyrosine kinase) and subsequently integrates wi

24 n Fyn kinase, independent of Syk, PI3K, Akt, Bruton's tyrosine kinase, and JAK2, and enhanced in the

25 tor tyrosine kinases spleen tyrosine kinase, Bruton's tyrosine kinase, and phosphatidylinositol 3-kin

26 Moreover, B cell linker protein, Bruton's tyrosine kinase, and phospholipase Cgamma2, whi

27 Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor o

28 h as the epidermal growth factor receptor or Bruton's tyrosine kinase, and we recently described thei

29 olipase Cgamma2 in mediating PKC activation, Bruton's tyrosine kinase- and phospholipase Cgamma2-defi

30 a possible mechanism of activation unique to Bruton's tyrosine kinase are provided.

31 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.

32 s of the anti-apoptotic tyrosine kinase BTK (Bruton's tyrosine kinase) as anti-leukemic agents with a

33 eficient (xid) mice possess mutations in the Bruton's tyrosine kinase (Btk kinase) gene and display d

34 Furthermore, LTB(4)-mediated Bruton's tyrosine kinase (BTK) activation is required fo

35 Bruton's tyrosine kinase (Btk) acts downstream of phosph

36 directly to, and stimulates the activity of, Bruton's tyrosine kinase (Btk) and a Ras GTPase-activati

37 d activated the nonreceptor tyrosine kinases Bruton's tyrosine kinase (Btk) and c-Src.

38 is an FDA-approved irreversible inhibitor of Bruton's tyrosine kinase (BTK) and IL-2 inducible T cell

39 have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell

40 Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and IL2-inducible T-cell

41 Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chron

42 B-cell-restricted factor that complexes with Bruton's tyrosine kinase (Btk) and its substrate, transc

43 or signaling and were more sensitive to both Bruton's tyrosine kinase (BTK) and MEK inhibition.

44 Both genetic inactivation of Bruton's tyrosine kinase (BTK) and pharmacological inhib

45 Two protein-tyrosine kinases, Bruton's tyrosine kinase (Btk) and Syk, and members of t

46 trated that Bright coimmunoprecipitates with Bruton's tyrosine kinase (Btk) and that these proteins a

47 his study, we show that both the stimulatory Bruton's tyrosine kinase (Btk) and the inhibitory SHIP-1

48 Phospholipase Cgamma2 (PLCgamma2) and Bruton's tyrosine kinase (BTK) are constituently associa

49 Defects in Bruton's tyrosine kinase (Btk) are responsible for X chr

50 Using Bruton's tyrosine kinase (BTK) as a clinically relevant

51 In the current report, we identified Bruton's tyrosine kinase (BTK) as a functional HIMF bind

52 In this study, we identify Bruton's tyrosine kinase (Btk) as a linker connecting BC

53 Bruton's tyrosine kinase (BTK) belongs to the TEC family

54 Bruton's tyrosine kinase (Btk) binds to phosphatidylinos

55 acologic inhibition and genetic knockdown of Bruton's tyrosine kinase (BTK) blocks AML blast prolifer

56 Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents a

57 Mutations in the gene encoding Bruton's tyrosine kinase (btk) cause the B cell deficien

58 Mutation of Bruton's tyrosine kinase (Btk) causes human X-linked aga

59 Loss of function of Bruton's tyrosine kinase (Btk) causes X-linked agammaglo

60 A fraction of Bruton's tyrosine kinase (Btk) co-localizes with actin f

61 gnaling supports Notch2(+/-)/NOD MZ B cells, Bruton's tyrosine kinase (Btk) deficiency was introduced

62 ap where and how the PHTH domain affects the Bruton's tyrosine kinase (BTK) domain.

63 The MZMO phenotype was reverted in SHIP/Bruton's tyrosine kinase (Btk) double knockout mice, thu

64 tionally, wild type or constitutively active Bruton's tyrosine kinase (Btk) enhanced, whereas the xid

65 Loss of Bruton's tyrosine kinase (Btk) function results in mouse

66 egulating B cell development and activation, Bruton's tyrosine kinase (Btk) functions downstream of m

67 Mutations of the Bruton's tyrosine kinase (btk) gene cause X-linked agamm

68 ime PCR revealed a higher mRNA expression of Bruton's tyrosine kinase (BTK) gene in DRG after CaP inj

69 the pleckstrin homology domain of the mouse Bruton's tyrosine kinase (btk) gene results in an X-link

70 These patients carry mutations in the Bruton's tyrosine kinase (BTK) gene that encode an essen

71 iciency (xid) due to a point mutation in the Bruton's tyrosine kinase (btk) gene.

72 Full-length Bruton's tyrosine kinase (BTK) has been refractory to st

73 (lo)) expressing 25% of endogenous levels of Bruton's tyrosine kinase (Btk) have B cell functional re

74 Mutation of Bruton's tyrosine kinase (Btk) impairs B cell maturation

75 ncovered a previously unappreciated role for Bruton's tyrosine kinase (Btk) in actin tail formation i

76 We investigated the role of Bruton's tyrosine kinase (Btk) in FcepsilonRI-dependent

77 rs have implicated a role for the Tec kinase Bruton's tyrosine kinase (Btk) in inflammatory cytokine

78 lly applied to the measurement of the RO for Bruton's tyrosine kinase (BTK) in the blood lysate of mo

79 ptor (IL-1R)-associated kinase 4 (IRAK4) and Bruton's tyrosine kinase (BTK) in these pathways.

80 A spontaneous mutation in Bruton's tyrosine kinase (Btk) induces a defect in B-cel

81 BDHI electrophile was further exploited in Bruton's tyrosine kinase (BTK) inhibitor design using a

82 olecule inhibitors of BCR signaling kinases, Bruton's tyrosine kinase (Btk) inhibitor ibrutinib and t

83 We show that an analogue of the covalent Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib beari

84 The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib effec

85 Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has b

86 The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has o

87 a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or th

88 e progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a

89 A Bruton's tyrosine kinase (BTK) inhibitor, administered a

90 A Bruton's tyrosine kinase (BTK) inhibitor, administered a

91 Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown prel

92 Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR si

93 Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficaciou

94 Bruton's tyrosine kinase (BTK) inhibitors block B cell r

95 Bruton's tyrosine kinase (BTK) inhibitors have revolutio

96 Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transform

97 Bruton's tyrosine kinase (BTK) inhibitors such as ibruti

98 Mutations in the gene encoding Bruton's tyrosine kinase (BTK) interfere with B cell pro

99 Bruton's tyrosine kinase (BTK) is a critical mediator of

100 Bruton's tyrosine kinase (BTK) is a critical signaling c

101 Bruton's tyrosine kinase (Btk) is a critical signaling m

102 Bruton's tyrosine kinase (Btk) is a critical transducer

103 Bruton's tyrosine kinase (btk) is a cytoplasmic kinase t

104 Bruton's tyrosine kinase (BTK) is a cytoplasmic protein

105 Cytoplasmic Bruton's tyrosine kinase (BTK) is a key component of B c

106 Bruton's tyrosine kinase (BTK) is a major drug target fo

107 Bruton's tyrosine kinase (BTK) is a major drug target in

108 Bruton's tyrosine kinase (BTK) is a mediator of the B-ce

109 Bruton's tyrosine kinase (BTK) is a member of the Src-re

110 Bruton's tyrosine kinase (BTK) is a member of the SRC-re

111 Bruton's tyrosine kinase (BTK) is a member of the Tec no

112 Bruton's tyrosine kinase (BTK) is a non-receptor bound k

113 Bruton's tyrosine kinase (BTK) is a non-receptor tyrosin

114 Here we show that Bruton's tyrosine kinase (BTK) is a novel modulator of p

115 ating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for

116 Bruton's tyrosine kinase (BTK) is a proven target in man

117 Bruton's tyrosine kinase (BTK) is a target for treating

118 Bruton's tyrosine kinase (Btk) is a Tec family non-recep

119 Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeuti

120 Bruton's tyrosine kinase (BTK) is an enzyme thought to b

121 Bruton's tyrosine kinase (BTK) is an essential enzyme fo

122 Bruton's tyrosine kinase (Btk) is critical for B cell pr

123 ed that functional, but not kinase-inactive, Bruton's tyrosine kinase (Btk) is critical for Bright ac

124 Bruton's tyrosine kinase (BTK) is crucial for FceRI-medi

125 Bruton's tyrosine kinase (Btk) is essential for B cell a

126 Bruton's tyrosine kinase (Btk) is essential for B-lineag

127 Bruton's tyrosine kinase (Btk) is essential for normal B

128 Bruton's tyrosine kinase (Btk) is essential for normal B

129 Bruton's tyrosine kinase (Btk) is expressed in a variety

130 Bruton's tyrosine kinase (BTK) is expressed in both B-ly

131 Bruton's tyrosine kinase (BTK) is important for B cell d

132 Bruton's tyrosine kinase (Btk) is mutated in X-linked ag

133 Bruton's tyrosine kinase (BTK) is pivotal in B cell acti

134 Bruton's tyrosine kinase (Btk) is required for normal B-

135 Bruton's tyrosine kinase (BTK) is targeted in the treatm

136 CD19 and Bruton's tyrosine kinase (Btk) may function along common

137 Bruton's tyrosine kinase (Btk) mediates TLR signaling in

138 Discovery of Bruton's tyrosine kinase (BTK) mutations as the cause fo

139 Bruton's tyrosine kinase (Btk) plays a central role in s

140 Bruton's tyrosine kinase (Btk) plays a critical role in

141 Bruton's tyrosine kinase (Btk) plays a crucial role in B

142 Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role i

143 Bruton's tyrosine kinase (BTK) plays an important role i

144 Bruton's tyrosine kinase (Btk) plays pivotal roles in ma

145 Inhibitors of Bruton's tyrosine kinase (BTK) possess much promise for

146 Bruton's tyrosine kinase (Btk) propagates B cell signali

147 n sequence to 89 kb of mouse sequence in the Bruton's tyrosine kinase (BTK) region.

148 Bruton's tyrosine kinase (BTK) regulates diverse cellula

149 Bruton's tyrosine kinase (BTK) regulates the functions o

150 The Tec kinase Bruton's tyrosine kinase (Btk) represents a key intermed

151 Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease calle

152 Defects in Bruton's tyrosine kinase (Btk) result in B cell immunode

153 Defects in the gene for Bruton's tyrosine kinase (Btk) result in the disorder X-

154 Mutations in Bruton's tyrosine kinase (Btk) result in X-linked agamma

155 Loss of function of Bruton's tyrosine kinase (Btk) results in X-linked immun

156 Bruton's tyrosine kinase (BTK) shows constitutive activi

157 in Gqalpha binds directly to the nonreceptor Bruton's tyrosine kinase (Btk) to a region composed of a

158 We demonstrated that the Bruton's tyrosine kinase (Btk) was required for multiple

159 y, we showed that dual targeting of TLR9 and Bruton's tyrosine kinase (BTK) was strongly synergistic

160 Previously, defects in the gene coding for Bruton's tyrosine kinase (Btk) were shown to result in d

161 uld directly increase the kinase activity of Bruton's tyrosine kinase (Btk) whose defects are respons

162 Therapy targeting Bruton's tyrosine kinase (BTK) with ibrutinib has transf

163 xid mice lack functional Bruton's tyrosine kinase (Btk), a component of the B cel

164 Bruton's tyrosine kinase (Btk), a critical component of

165 Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine k

166 Bruton's tyrosine kinase (Btk), a downstream effector of

167 an interact physically and functionally with Bruton's tyrosine kinase (Btk), a hematopoietic non-rece

168 Here, we investigate Bruton's tyrosine kinase (BTK), a key B-cell kinase, as

169 ated cells is mediated by stimulation of the Bruton's tyrosine kinase (BTK), a member of the Src-rela

170 Bruton's tyrosine kinase (Btk), a member of the Tec fami

171 Bruton's tyrosine kinase (BTK), a member of the Tec fami

172 Bruton's tyrosine kinase (BTK), a member of the TEC fami

173 Bruton's tyrosine kinase (BTK), a member of the Tec kina

174 Bruton's tyrosine kinase (BTK), a non-receptor tyrosine

175 Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine k

176 Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine k

177 Bruton's tyrosine kinase (BTK), a Tec family tyrosine ki

178 Bruton's Tyrosine Kinase (BTK), a Tec-family tyrosine ki

179 Bruton's tyrosine kinase (Btk), a Tec-family tyrosine ki

180 Bruton's tyrosine kinase (BTK), an essential component o

181 promoters and requires Bright dimerization, Bruton's tyrosine kinase (Btk), and the Btk substrate, T

182 Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of

183 Mice deficient in Bruton's tyrosine kinase (Btk), despite their known defe

184 In cells deficient in Bruton's tyrosine kinase (Btk), Gi-coupled receptors fai

185 Ibrutinib, a drug that inhibits Bruton's tyrosine kinase (BTK), has improved the overall

186 an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatmen

187 The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B-cell

188 The signaling mediator, Bruton's tyrosine kinase (Btk), is required for certain

189 hree protein tyrosine kinases, Lyn, Syk, and Bruton's tyrosine kinase (Btk), leading to the secretion

190 inhibitors targeting BCR-associated kinases [Bruton's tyrosine kinase (BTK), phosphoinositide 3-kinas

191 been delineated based on the involvements of Bruton's tyrosine kinase (Btk), protein kinase C (PKC),

192 ymphocytic leukemia (CLL) with inhibitors of Bruton's tyrosine kinase (BTK), such as ibrutinib, is li

193 e now report that Bright coprecipitates with Bruton's tyrosine kinase (Btk), the defective enzyme in

194 inical phenotype of patients with defects in Bruton's tyrosine kinase (Btk), the gene that is abnorma

195 Bruton's tyrosine kinase (Btk), the target of inactivati

196 ing ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rit

197 llular dsDNA sensor that, upon activation by Bruton's tyrosine kinase (BTK), triggers type I IFN prod

198 erleukin-2-inducible T-cell kinase (Itk) and Bruton's tyrosine kinase (Btk), two Tec-family kinases e

199 nt (IRC) binders, affects the degradation of Bruton's Tyrosine Kinase (BTK), we serendipitously disco

200 activity of a purified non-receptor kinase, Bruton's tyrosine kinase (Btk), whereas purified alpha-s

201 An AMPK PHICS directed against Bruton's tyrosine kinase (BTK), which is a driver of sev

202 The PH domain of Bruton's tyrosine kinase (Btk), which is mutated in the

203 peration between the protein tyrosine kinase Bruton's tyrosine kinase (Btk), which regulates the acti

204 Overexpression of human Bruton's tyrosine kinase (Btk), which was activated by H

205 Mast cells derived from Bruton's tyrosine kinase (Btk)-defective xid or btk null

206 posure of wild-type DT40 lymphoma B cells or Bruton's tyrosine kinase (BTK)-deficient DT40 cells reco

207 Bruton's tyrosine kinase (Btk)-deficient human B cells e

208 We show here that Bruton's tyrosine kinase (BTK)-deficient macrophages fai

209 1 (MAV-1) infection of B-cell-deficient and Bruton's tyrosine kinase (Btk)-deficient mice resulted i

210 ther define the nature of the protective Ab, Bruton's tyrosine kinase (Btk)-deficient mice were chara

211 vent include C-terminal Src kinase (Csk) and Bruton's tyrosine kinase (Btk).

212 BCR signaling, which is mediated in part by Bruton's tyrosine kinase (BTK).

213 TAT5A can serve as a functional substrate of Bruton's tyrosine kinase (BTK).

214 ly kinases is required for the activation of Bruton's tyrosine kinase (Btk).

215 (XLA) encodes a novel protein kinase termed Bruton's tyrosine kinase (Btk).

216 homology and Tec homology (PH-TH) module of Bruton's tyrosine kinase (Btk).

217 ells and MCL cell lines expressing wild-type Bruton's tyrosine kinase (BTK).

218 els of the key downstream signaling molecule Bruton's tyrosine kinase (BTK).

219 Ibrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK).

220 ults from mutations within the gene encoding Bruton's tyrosine kinase (BTK).

221 which is caused by mutations in the gene for Bruton's tyrosine kinase (Btk); however, there are femal

222 In contrast, the Bruton's tyrosine kinase (Btk)PH domain specifically bou

223 cute myeloid leukaemia have high activity of Bruton's tyrosine-kinase (BTK) in their blast cells comp

224 ty of kinases (spleen tyrosine kinase [Syk], Bruton's tyrosine kinase [Btk], phosphatidylinositol 3-k

225 In addition, T2 cells from Bruton's tyrosine kinase-deficient Xid mice failed to ge

226 s and inhibited Th2 cytokine production in a Bruton's tyrosine kinase-dependent manner.

227 ndent differences in Lyn phosphorylation and Bruton's tyrosine kinase distribution were observed betw

228 osine kinase R544 on the activation loop and Bruton's tyrosine kinase E445 on the C-helix also aids i

229 PUVA caused poor membrane binding of Akt and Bruton's tyrosine kinase effectors following activation

230 Suppressed expression of c-Src or downstream Bruton's tyrosine kinase, Ets1, Ets2, USF1, or USF2 bloc

231 hich express Bmx and Src as their major Btk (Bruton's tyrosine kinase) family and Src family tyrosine

232 T-cell kinase (Itk) is a member of the Btk (Bruton's tyrosine kinase) family of tyrosine kinases.

233 truct of the pleckstrin homology domain from Bruton's tyrosine kinase (GFP-BTK-PH) localized in intra

234 dentified a novel signaling pathway (c-Src-->Bruton's tyrosine kinase-->transcription factors Ets1, E

235 In B lymphocytes, Bruton's tyrosine kinase has been identified as a TFII-I

236 to homeostatic B cell proliferation require Bruton's tyrosine kinase; however, c-Rel, a Bruton's tyr

237 entify the alpha isoform of the inhibitor of Bruton's tyrosine kinase (IBTKalpha) as a member of the

238 identified the alpha isoform of inhibitor of Bruton's tyrosine kinase (IBTKalpha) as being subject to

239 Mutations in Bruton's tyrosine kinase, immunoglobulin heavy chain and

240 miR-185 is a microRNA (miR) that targets Bruton's tyrosine kinase in B cells, with reductions in

241 levant phosphorylation of the target protein Bruton's tyrosine kinase in cells.

242 phosphatases SHP-1 and SHP-2 but depends on Bruton's tyrosine kinase in DT40 cells.

243 I physically and functionally interacts with Bruton's tyrosine kinase in murine B cells.

244 ngagement bypasses or mitigates the need for Bruton's tyrosine kinase in subsequent BCR signaling for

245 -gamma2 (PLCgamma2), Vav, B cell linker, and Bruton's tyrosine kinase in the formation of highly coor

246 ficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor

247 of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory pati

248 Bruton's tyrosine kinase; however, c-Rel, a Bruton's tyrosine kinase-induced NF-kappaB/Rel transcrip

249 The activation of N-WASP is suppressed by Bruton's tyrosine kinase-induced WASP activation, and is

250 ying mechanism associated with resistance to Bruton's tyrosine kinase inhibition by ibrutinib in both

251 Acalabrutinib, a next-generation Bruton's tyrosine kinase inhibitor (BTKi), associates wi

252 integrated safety profile of evobrutinib, a Bruton's tyrosine kinase inhibitor (BTKi), using pooled

253 le blocking both BCRs and TLR-MyD88 by using Bruton's tyrosine kinase inhibitor and histone deacetyla

254 The Bruton's tyrosine kinase inhibitor ibrutinib effectively

255 The novel Bruton's tyrosine kinase inhibitor ibrutinib has demonst

256 Furthermore, we demonstrate that the Bruton's tyrosine kinase inhibitor ibrutinib or the PI3K

257 synergy, additivity, and antagonism with the Bruton's tyrosine kinase inhibitor ibrutinib, which targ

258 ressive clinical responses achieved with the Bruton's tyrosine kinase inhibitor ibrutinib.

259 in a manner quantitatively comparable to the Bruton's tyrosine kinase inhibitor ibrutinib.

260 ng, prompting us to combine AZD8835 with the Bruton's tyrosine kinase inhibitor ibrutinib.

261 chronic lymphocytic leukemia (CLL) with the Bruton's tyrosine kinase inhibitor ibrutinib.

262 ortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kinase inhibitor ibrutinib.

263 and in vivo and synergizes strongly with the Bruton's tyrosine kinase inhibitor ibrutinib.

264 Ibrutinib is a clinically approved Bruton's tyrosine kinase inhibitor that inhibits mast ce

265 mantle cell lymphoma following prior failed Bruton's tyrosine kinase inhibitor therapy, with an over

266 Terreic acid (a Bruton's tyrosine kinase inhibitor) and pergolide (a dop

267 Ibrutinib, a novel oral Bruton's tyrosine kinase inhibitor, has shown single-dru

268 The oral Bruton's tyrosine kinase inhibitor, ibrutinib, has recen

269 ignaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor.

270 cell lymphoma (DLBCL) subtypes vulnerable to Bruton's tyrosine kinase inhibitors (BTKis), but is chal

271 ammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and ma

272 In summary, we show that PI3Kdelta or Bruton's tyrosine kinase inhibitors increase genomic ins

273 Bruton's tyrosine kinase inhibitors remain in the precli

274 (e.g. spleen tyrosine kinase inhibitors and Bruton's tyrosine kinase inhibitors) or the downstream p

275 Among Bruton's tyrosine kinase inhibitors, acalabrutinib has g

276 Bruton's tyrosine kinase is intimately involved in signa

277 Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for pa

278 en revealed that a BCR signalling component, Bruton's tyrosine kinase, is essential for the survival

279 The human inhibitor of Bruton's tyrosine kinase isoform alpha (IBtkalpha) is a

280 etermined the x-ray crystal structure of the Bruton's tyrosine kinase kinase domain in its unphosphor

281 NMR titration experiments using a Btk (Bruton's tyrosine kinase) kinase domain as a surrogate f

282 inase inhibitors and flavopiridol to inhibit Bruton's tyrosine kinase localization at the membrane an

283 was observed in mutated WM cells exposed to Bruton's tyrosine kinase, mammalian target of rapamycin,

284 The combined use of TMP with Bruton's tyrosine kinase or interleukin-1 receptor-assoc

285 production in a manner that is dependent on Bruton's tyrosine kinase, p38 MAPK, and TANK-binding kin

286 1), as demonstrated by the individual use of Bruton's tyrosine kinase, p38 MAPK, and TBK1 inhibitors.

287 judged by increased levels of phosphorylated Bruton's tyrosine kinase (pBtk), phosphorylated Spleen t

288 We show that the Bruton's tyrosine kinase PH domain binds to PtdIns-3,4,

289 rmation, which resulted in the activation of Bruton's tyrosine kinase, phospholipase and phosphoinosi

290 uces an alternate signaling pathway in which Bruton's tyrosine kinase, PI3K, phospholipase Cgamma2, a

291 , and fostamatinib (respective inhibitors of Bruton's tyrosine kinase, PI3Kdelta, and spleen tyrosine

292 cks chemokine-induced triggering of JAK2 and Bruton's tyrosine kinase protein tyrosine kinases and of

293 conserved electrostatic interaction between Bruton's tyrosine kinase R544 on the activation loop and

294 ity of a gain-of-function variant (S180A) of Bruton's tyrosine kinase that evokes B cell malignancy p

295 and phosphorylated tyrosine kinases Lyn and Bruton's tyrosine kinase to membrane rafts after Fc alph

296 Pharmacodynamic data showed Bruton's tyrosine kinase was fully occupied (>90% occupa

297 Activity of Bruton's tyrosine kinase was required for RP105-mediated

298 In a study of Bruton's tyrosine kinase, we find that the use of Previe

299 s are dependent on the BCR signal transducer Bruton's tyrosine kinase, which is dispensable for the T

300 burden in the spleens of B1a cell-deficient Bruton's tyrosine kinase x-linked immunity-deficient (BT